Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma

Table 1

Characteristics of patients and their relationship with the expression of HER2.

Characteristic	HER2
	Absent; (%)	Indeterminate; (%)	Present; (%)	Total; (%)	HER2 present %
Sex
Male	59 (48.7)	5 (4.1)	2 (1.6)	66 (54.5)	3.1	0.
Female	52 (42.9)	1 (0.8)	2 (1.6)	55 (45.5)	3.6
Tumor site
Proximal	40 (33.1)	0 (0.0)	1 (0.8)	41 (33.9)	2.4	0.
Distal	71 (58.7)	6 (4.9)	3 (2.5)	80 (66.1)	3.8
Surgery
Gastrectomy subtotal	92 (76.1)	6 (4.9)	4 (3.3)	102 (84.3)	3.9	0.
Total gastrectomy	19 (15.7)	0 (0.0)	0 (0.0)	19 (15.7)	0.0
Tumor depth
T1	35 (28.9)	1 (0.8)	0 (0.0)	36 (29.7)	0.0	0.
T2	12 (9.9)	1 (0.8)	2 (1.6)	15 (12.4)	13.3
T3	22 (18.2)	2 (1.6)	0 (0,0)	24 (19.8)	0.0
T4	42 (34.7)	2 (1.6)	2 (1.6)	46 (38.1)	4.3
Lymph node involvement
N0	55 (45.4)	2 (1.6)	1 (0.8)	58 (47.9)	1.7	0.
N1	12 (9.9)	0 (0.0)	0 (0.0)	12 (10.7)	0.0
N2	13 (10.7)	3 (2.5)	0 (0.0)	16 (13.2)	0.0
N3	31 (25.6)	1 (0.8)	3 (2.5)	35 (28.9)	8.6
Stage
I	41 (33.9)	2 (1.6)	1 (0.8)	44 (36.4)	2.2	0.
II	20 (16.5)	0 (0.0)	0 (0.0)	20 (16.5)	0.0
III	50 (41.3)	4 (3.3)	3 (2.5)	57 (47.1)	5.2
Histological type
Well-differentiated	18 (14.9)	1 (0.8)	0 (0.0)	19 (15.7)	0.0	0.
Mod. differentiated	33 (27.3)	5 (4.1)	3 (2.5)	41 (33.9)	7.3
Little differentiated	54 (44.7)	0 (0.0)	1 (0.8)	55 (45.4)	1.8
Nondifferentiated	6 (4.9)	0 (0.0)	0 (0.0)	6 (4.9)	0.0
Angiolymphatic invasion
Yes	61 (50.4)	5 (4.1)	4 (3.3)	70 (57.8)	5.7	0.
No	50 (41.3)	1 (0.8)	0 (0.0)	51 (42.1)	0.0
Perineural invasion
Yes	50 (41.3)	2 (1.6)	1 (0.8)	53 (43.8)	1.9	0.
No	61 (50.4)	4 (3.3)	3 (2.5)	68 (56.2)	4.4
Adjuvant treatment
Yes	50 (41.3)	2 (1.6)	3 (2.5)	55 (45.4)	5.4	0.
No	61 (50.4)	4 (3.3)	1 (0.8)	66 (54.6)	1.5
Relapse
Yes	14 (11.6)	0 (0.0)	1 (0.8)	15 (12.4)	6.6	0.
No	97 (80.2)	6 (4.9)	3 (2.5)	106 (87.6)	2.8
Death
Yes	45 (37.2)	3 (2.5)	2 (1.6)	50 (41.3)	4.0	0.
No	66 (54.5)	3 (2.5)	2 (1.6)	71 (58.7)	2.8

-square test.
’s exact test.